Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has successfully included several of its products in the National Medical Insurance Directory, which is expected to enhance market access and potentially increase sales revenue for the company [1] Group 1: Inclusion of Products - The following products have been newly included in the National Medical Insurance Directory: - Injection of Rukang Qutuzumab - Apixaban Famitinib Capsules - Injection of Funaqi Qutuzumab - Sulfate of Amagatin Tablets - Injection of Phosphororapitant Palonosetron - Injection of Ruikaxizumab - Acetate of Abiraterone Tablets (II) - Liposomal Injection of Irinotecan (II) - Regaglitin Metformin Tablets (I)/(II) - Perfluorohexyl Octane Eye Drops [1] - The following products have successfully added new indications to the National Medical Insurance Directory: - Injection of Karilizumab - Fluorouracil Capsules - Injection of Fumaric Acid Tegafur [1] - The following products have successfully renewed their contracts to remain in the National Medical Insurance Directory: - Maleate of Pyrotinib Tablets - Hecorapam Ethanolamine Tablets - Phosphate of Regaglitin Tablets - Injection of Tofisopam - Injection of Sulfapegfilgrastim [1] Group 2: Adjustments and Management - The following products have had new indications added and adjusted to regular directory management: - Mesylate of Apatinib Tablets - Liposomal Injection of Bupivacaine [1]